RFP
LGND icon

Root Financial Partners’s Ligand Pharmaceuticals LGND Stock Holding History

Root Financial Partners’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.79K Buy
19
+12
+171% +$2.37K ﹤0.01% 2054
2025
Q4 		$1.32K Buy
+7
New +$1.34K ﹤0.01% 2056

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Root Financial Partners's LGND Position: Q1 2026 in Review

Root Financial Partners increased its Ligand Pharmaceuticals (LGND) stake by 171% in Q1 2026, buying an estimated $2.37K and bringing the position to 19 shares worth $3.79K. The position accounts for ﹤0.01% of the portfolio, ranked #2054.

Root Financial Partners first reported a position in LGND in Q4 2025 and has held it in 2 quarters since. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • Root Financial Partners held 19 shares of Ligand Pharmaceuticals worth $3.79K as of Q1 2026.
  • Root Financial Partners bought 12 Ligand Pharmaceuticals shares in Q1 2026, an estimated $2.37K.
  • Ligand Pharmaceuticals made up ﹤0.01% of Root Financial Partners's portfolio in Q1 2026, its #2054 holding.
  • Root Financial Partners first reported a position in Ligand Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Root Financial Partners's 13F filing for Q1 2026, filed 24 Apr 2026.